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S U M M A R Y
Objectives: The aim of this study was to highlight the increasing chance of Western physicians
encountering patients (both immigrants and expatriates/travelers) seeking help for loiasis.
Methods: We describe three cases of imported loiasis observed at two hospitals in Italy and France, and
present a review of all previously published cases in the medical literature in the last 25 years (1986–
2011). The search was performed using PubMed and Scopus databases using the terms ‘‘Loa loa’’ AND
‘‘loiasis’’.
Results: We reviewed 101 cases of imported loiasis of which 61 (60.4%) were reported from Europe and
31 (30.7%) from the USA. Seventy-ﬁve percent of infestations were acquired in three countries:
Cameroon, Nigeria, and Gabon. Overall, peripheral blood microﬁlariae were detected in 61.4% of patients,
eosinophilia in 82.1%, eye worm migration in 53.5%, and Calabar swellings in 41.6%. However, Calabar
swellings and eosinophilia were more common among expatriates/travelers, whereas African
immigrants were more likely to have microﬁlaremia. Eye worm migration was observed in a similar
proportion in the two groups. Only 35 patients (including the three described here) underwent clinical
follow-up for a median period of 10.5 months (range 1–84 months); clinical relapse occurred in three of
these patients and persistence or reappearance of blood microﬁlaria in another two.
Conclusions: Due to increasing travel and the migration of people from the endemic countries of West
Africa to Europe and the USA, we speculate on the possible emergence of loiasis. Western physicians
should be aware of the typical (eye worm migration and Calabar swellings) as well as unusual clinical
presentations.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Loiasis is a neglected nematode infestation that is endemic in
the rainforests of western and central Africa, from a latitude of
8–108 N to 58 S. The disease is transmitted to man by tabanid ﬂies of
the genus Chrysops.1 It is especially common in Cameroon, the
Republic of Congo, the Democratic Republic of Congo, the Central
African Republic, Gabon, Equatorial Guinea, and Nigeria.1,2 In a
recent survey using the rapid assessment procedure for loiasis
(identiﬁed with the acronym RAPLOA), which combines a history
of eye worms with the level of endemicity of the infection, it was* Corresponding author. Tel.: +39 0 2 39042688; fax: +39 0 2 50319758.
E-mail address: spinello.antinori@unimi.it (S. Antinori).
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http://dx.doi.org/10.1016/j.ijid.2012.05.1023estimated that nearly 30 million people live in high to intermediate
risk areas with a prevalence of eye worm history exceeding 20%.2,3
In the medical literature loiasis is also referred to as ‘African eye
worm’ because one of its possible manifestations is the pathogno-
monic migration of the adult worm under the conjunctiva.4 Several
local names, such as yolo li (yolo = worm; li = eye) and guilde´ guite´
(guilde´ = worm; guite´ = eye) are used by the different ethnic
groups in eastern Cameroon to indicate the disease.5 The other
most common clinical presentation of loiasis is the intermittent
appearance of subcutaneous, non-pitting and non-tender edema,
which is frequently localized to the extremities; these are also
known as ‘Calabar swellings’.1
We describe herein three patients with imported ocular loiasis
(two African immigrants presenting over the course of 12 months
and one French traveler) managed at two medical centers, one inses. Published by Elsevier Ltd. All rights reserved.
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provide a discussion on the clinical management of the disease and
a review of all imported (in non-endemic countries) cases of loiasis
published from 1986 up to December 2011.6–92 Because of
increased immigration to Europe and the USA from areas endemic
for loiasis and also an increase in travel to these endemic areas,
physicians need to be familiar with the clinical manifestations and
the correct management of this neglected ﬁlariasis.
2. Methods
We retrieved all articles published in the English, French,
German, Italian, and Spanish language literature over the last
25 years (1986–2011) using PubMed and Scopus. The search was
conducted using the terms ‘‘Loa loa’’ AND ‘‘loiasis’’. Additional
cases were identiﬁed by reviewing the reference lists of the
original articles. Single case reports identiﬁed and published from
countries endemic for loiasis were excluded.
For the purpose of the present study patients were deﬁned as
follows: (1) as immigrants when coming from endemic countries
and subsequently residing in non-endemic countries; (2) as
expatriates when born and raised in non-endemic countries and
subsequently temporarily resident in endemic countries for
occupation or humanitarian purposes, and returning to their
original country when their assignment was completed; (3) as
travelers when traveling for less than 2 months in endemic
countries. Eosinophilia was deﬁned as an eosinophil count in the
blood exceeding 0.5  109 cells/l, or a percentage 8% when an
absolute number was not available.
In the three newly reported cases, the diagnosis of ocular loiasis
was based on the observation of the passage of the adult worm in
the eyelid or under the conjunctiva. The presence of microﬁlariae
was determined by examining thin and thick blood smears
obtained at noon and stained with Giemsa.
A nested PCR ampliﬁcation was performed in two cases using
the primers originally described by Toure´ et al., which amplify the
repeat 3 sequence (15r3) of the gene encoding the Loa loa 15-kD
polyprotein, with minor modiﬁcations.93 The presence and
integrity of human genomic DNA in each sample was assessed
by performing a simple PCR using human b-globin-speciﬁc
primers that amplify a 252-bp fragment. Estimation of the
circulating parasitemia burden was obtained by performing eight
serial 5-fold dilutions starting from 1 mg of whole blood DNA for
each time-point and performing a simple PCR using primers
15r31–15r32 for Loa loa and b-globin for human genomic DNA
ampliﬁcation, as previously described. Brieﬂy, PCR conditions were
identical to those described in the nested PCR protocol, except that
the total number of ampliﬁcation cycles was of 60 instead of 40.
The Loa loa parasite burden was arbitrarily expressed as the
number of parasites/150 000 human cells using 5 copies of
the parasite sequences and 5 copies of human b-globin as
the sensitivity of the simple PCR reaction. Since it is known that
the repeat 3 region of the 15-kD polyprotein is repeated three
times in the genome, the number of parasites present was
calculated as a third of the number of the estimated DNA copies
present in each sample.
Data were analyzed using the Chi-square test for dichotomous
variables and the two-tailed t-test or Mann–Whitney U-test for
continuous variables.
3. Case reports
3.1. Patient 1
A 27-year-old woman originating from Cameroon presented to
the emergency department (ED) of a hospital in Legnano (Italy) inJuly 2009, complaining of a ‘foreign body sensation’ in her left eye,
which had started several hours before. On examination there was
a left conjunctival injection, and a subconjunctival yellowish
worm-like organism was seen moving in the inferior fornix
(Figure 1A). Following a telephone consultation, a provisional
diagnosis of ocular loiasis was made and the patient was
discharged from the ED and referred to our outpatient clinic. On
evaluation 2 days later no worm was visible on gross examination
or by slit lamp evaluation. On physical examination she appeared
to be a healthy pregnant woman at week 16 of gestation. She had
been living in Italy since 2002 and initially did not recall any
previous symptoms that could be relevant to the present diagnosis.
However, she subsequently referred to a similar episode of ocular
worm migration that had occurred when she was 17 years old and
living in Cameroon.
Additional investigations showed a white blood cell count of
6.9  109/l with 13% eosinophils; liver enzymes and renal function
were normal. A peripheral blood smear drawn at 2 p.m. was
positive for the presence of sheathed microﬁlariae of Loa loa
(Figure 1B). Subsequent examination of a wet peripheral blood
sample under light microscopy conﬁrmed these organisms to be
viable and motile. In consideration of the early pregnancy we
decided not to treat the patient immediately. Instead we checked
the patient at regular intervals (19, 24, 27, 31, and 34 weeks of
gestation) and on each occasion conﬁrmed the persistence of blood
microﬁlaremia and eosinophilia. During this time the patient
complained of another episode of ocular worm migration and two
episodes of swelling of the right ankle. In January 2010 she had a
normal labor and delivered a healthy female baby weighing
3900 g. Examinations of the cord and peripheral blood of the
newborn were negative for the presence of microﬁlariae. In
contrast, rare microﬁlariae could be observed in the intervillar
vascular lacunae of the mother’s placenta (Figure 1C).
After delivery, the patient was treated twice (1 month apart)
with a single dose (200 mg/kg) of ivermectin (Stromectol1, Merck
Sharp & Dohme, Whitehouse Station, NJ, USA) associated with
prednisone, but this therapy was unsuccessful in clearing the
peripheral blood microﬁlariae. Four months after delivery, when
the patient had stopped breast-feeding, treatment with albenda-
zole (Zentel1) 400 mg twice daily for 4 weeks was attempted, but
after the end of treatment peripheral blood microﬁlariae were still
present, albeit at a lower concentration, as evidenced by a semi-
quantitative nested PCR (Figure 1D). We thus obtained diethylcar-
bamazine (DEC) and treated the patient accordingly (6 mg/kg/day
for 21 days). No microﬁlariae could be detected 3 months later in a
sample of peripheral blood collected at noon, either by direct
microscopic examination or by nested PCR (Figure 2). Similarly, the
patient’s 9-month-old daughter tested negative for blood micro-
ﬁlariae and for the presence of Loa loa-speciﬁc DNA. At the last
follow-up visit, 17 months after the end of DEC treatment, no
recurrences were registered and blood microﬁlariae were still
undetectable.
3.2. Patient 2
A 25-year-old African woman from Douala, Cameroon pre-
sented to the ophthalmic ED of Fatebenefratelli e Oftalmico
Hospital in Milan in May 2010 complaining of pruritus of 24-h
duration and a burning and foreign body sensation in her left eye.
On ophthalmological examination, a translucent, coiled and motile
worm was visualized subconjunctivally in the lower temporal
quadrant of the eye (Figure 3, A and B). The eye was slightly
injected but otherwise normal. A diagnosis of ocular loiasis was
made based on the epidemiology, clinical history, and ocular
images, and the patient was referred to our outpatient clinic the
following day. Her past medical history was unremarkable and she
Figure 2. Schematic representation of the clinical outcome of patient 1 (E, eosinophils; mff, microﬁlariae).
Figure 1. (A) Patient 1: appearance of the yellowish worm migrating under the patient’s left conjunctiva. (B) Microﬁlaria of Loa loa in peripheral blood ﬁlm; Giemsa 300. (C)
Microﬁlaria of Loa loa observed in the intervillous space of the placenta of patient 1. (D) PCR on peripheral blood of patient 1: lane A, 5 parasites/150 000 cells T0, T1, T2, T3
(from July 16 to July 19, 2010); lane B, 1 parasite/150 000 cells T4, T5, T6 (from July 20 to July 22, 2010); lane C, undetectable parasite (i.e., <1 parasite/150 000 cells) at T7
(October 28, 2010).
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Figure 3. (A) Cordon-like appearance of the worm in the inferior bulbar conjunctiva of patient 2. (B) Translucent white thread-like structure of the adult worm visualized
under a slit lamp in patient 2. (C) Subcutaneous thread-like swelling under the inferior right eyelid of patient 3. (D) Cordon-like appearance of the worm in the inferior bulbar
conjunctiva of patient 3.
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journey to Cameroon having occurred 1 year before. On evaluation
she had conjunctival injection of the left eye and the worm was still
visible on gross examination. Blood analysis showed normal
leukocytes (5.310  109/l) without eosinophilia (1.5%). Peripheral
blood smears obtained for 3 consecutive days at noon were always
negative for microﬁlariae. On the second day of observation the
worm disappeared from her eye. She received a single day
treatment of ivermectin 200 mg/kg (total dose 12 mg), followed by
a 21-day course of DEC 4 weeks later. No recurrence of the ocular
worm passage was observed during the ensuing 6-month follow-
up. Interestingly, Loa loa-speciﬁc peripheral blood nested PCR was
repeatedly negative, both before the inception of anthelmintic
therapy and during the relatively short follow-up, in accordance
with the results of direct microscopic examination.
3.3. Patient 3
In 1998, a 58-year-old French man was admitted to the
infectious disease and tropical medicine department in Marseille,
France for a mobile subcutaneous lesion of the trunk that had
appeared a few days after surgery of an aortic aneurysm,
performed after an autologous blood transfusion. Within a few
days, he complained of pruritus associated with a mobile foreign
body in the eyelid and conjunctiva in the right eye (Figure 3, C and
D). His past medical history was unremarkable; however in 1990
he had stayed for several months in Mouila, Gabon. On initial
clinical examination, only a diffuse pruritus was noted, without
fever. Laboratory tests revealed 6.5  109 leukocytes/l with 16%
eosinophils and normal liver enzymes and renal function. Total IgE
was elevated (3700 kIU/l). A chest radiograph was normal. A
peripheral blood smear was positive for the presence of sheathed
microﬁlariae of Loa loa with the detection of 20–30 parasites/ml.
The patient then received a course of DEC 400 mg/day for 15 days,followed a few months later by 3 successive courses of 6 weeks of
doxycycline. Doxycycline was used with the intention of reducing
the microﬁlaremia by eradicating Wolbachia, a symbiont of ﬁlarial
worms. At the time of treatment it had not yet been demonstrated
that Loa loa does not contain Wolbachia.94 However, subcutaneous
passage and ocular worm migration recurred, together with
the persistence of peripheral blood eosinophilia. He ﬁnally
received a single day treatment with ivermectin 200 mg/kg (total
dose 12 mg) in 2005 and showed no recurrence at the 5-year
follow-up.
4. Literature review
From an analysis of the literature for the period 1986–2011, we
identiﬁed 46 patients with imported loiasis presenting with eye
worm migration: 27 immigrants from Africa and 19 expatriates or
travelers, of whom 12 were from Europe, two each from the USA
and Africa, and the remaining three patients from Australia, Sri
Lanka, and Israel. These 46 cases, plus the two migrant patients in
the case reports above, are summarized in Table 1. We identiﬁed a
further 52 patients presenting initially with other clinical
manifestations: 23 immigrants from Africa and one from
Philippines and 28 expatriates and travelers, of whom 12 were
from Europe, 14 from the USA, and one each from New Zealand and
Japan. These 52 cases, plus the expatriate patient described in the
case reports above, are summarized in Table 2. Sixty-one cases
(60.4%) were reported from Europe8,12,16,17,19–21,24,26–29,31–
37,42,43,45–48,51–54,56,59,61,63,64,67,69,70,72–74,77,79–83,86–88,90–92 (in-
cluding cases in the present report (PR)) and 31 (30.7%) from the
USA.6,13,15,22,23,25,30,40,41,44,49,50,55,57,58,60,62,65,66,68,71,75,76,78,85,89
Overall, both sexes were equally represented, but with a
predominance of females among expatriates/travelers and of males
among immigrants (Table 3). The median age was 30 years (range
4–73 years), with no difference between expatriates/travelers and
Table 1
Forty-eight cases of imported loiasis presenting with ocular involvement (‘eye worm migration’) published between January 1986 and December 2011
Reference,
year of
publication
Sex, age
(years)
Status Country of
origin
Country of residency/travel Microﬁlaremia/
concentration
WBC/eosinophils,109/l
(% eosinophils)
Other manifestations Treatment/follow-up
6, 1987 M, 25 Immigrant Cameroon USA/Cameroon 15 years earlier No 3.1/0.434 (14%) No Surgical extraction; DEC 3 weeks/NR
7, 1988 M, 20 Immigrant Nigeria India, 9 months residency/Nigeria Yes/NR NR/ (28%) Calabar swellings;
subcutaneous worm
migration; fever;
urticarial rash
Surgical extraction; DEC 3 weeks/9
months asymptomatic
8, 1988 F, 29 Traveler Germany Germany/West Africaa Yes/9900 mff/ml 20.0/11.200 (56%) Eyelid worm migration Apheresis (2 cycles) + ST/NR
9, 1989 F, 32 Traveler Zambia Zimbabwe/Zambia No NR/ (28%) No Surgical extraction; DEC 3 weeks/NR
10, 1989 F, 14 Expatriate Sri Lanka Sri Lanka/Nigeria for 6 years No 12.8/2.688 (21%) Calabar swellings Surgical extraction/DEC 5 weeks/NR
11, 1990 M, 35 Expatriate Germany Australia 30 months/Africaa Yes/NR NR/ (38%) No DEC 3 weeks/NR
12, 1991 M, NR Expatriate Italy Italy/Nigeria for 3 years Yes/NR 11.5/3.105 (27%) No Surgical extraction; steroids + DEC 3
weeks/12 months asymptomatic
13, 1992 M, 36 Immigrant Ghana USA 6 years residency/Nigeria
several times before leaving
Ghana
Yes/2000 mff/ml 7.1/0.994 (14%) No Surgical extraction; apheresis +
steroids + DEC 3 weeks/NR
14, 1992 F, 28 Expatriate Australia Australia/West Central Africaa No NR/yes No Surgical extraction; DEC 3 weeks/12
months asymptomatic
15, 1992 M, 19 Immigrant Nigeria USA/Nigeria No NR No Surgical extraction/NR
16, 1993b M, 57 Expatriate Italy Italy/Africaa for 20 years Yes/NR NR/yes No Surgical extraction, DEC 3 weeks/4 months
(1 relapse of microﬁlaremia at 3 months)
17, 1993 F, NR Immigrant Nigeria UK/Nigeria NR NR/ (16%) No Surgical extraction; DEC 3 weeks/18
months asymptomatic
18, 1993 F, 52 Expatriate Israel Israel/Nigeria for 10 years
(returned 7 years before
presentation)
Yes/NR 8.0/2.080 (26%) Calabar swellings Steroids + DEC 3 weeks/NR
19, 1995 F, 23 Traveler Germany Germany/Cameroon 2 years before Yes/2000 mff/ml NR/ (13%) No Surgical extraction; steroids +
DEC 3 weeks/NR
20, 1995 F, 31 Expatriate Italy Italy/Cameroon Yes/NR NR/ (40%) Calabar swellings DEC 3 weeks/NR
21, 1995 M, 31 Immigrant Ghana Germany/Ghana Yes/3600 mff/ml NR No Surgical extraction; DEC 3 weeks +
mebendazole/NR
22, 1996 M, 32 Immigrant Ghana USA 3 years residency/Ghana Yes/NR 11.0/4.290 (39%) Lethargy after
starting DEC; Loa
loa identiﬁed in CSF
Steroids + DEC 3 weeks/NR
23, 1998 M, 40 Immigrant Ghana USA 12 years residency/Nigeria,
Ethiopia
Yes/3300 mff/ml NR/0.617 No Apheresis + steroids + DEC 3 weeks/
12 months asymptomatic
24, 1998 M, 26 Immigrant Cameroon Germany 6 weeks/Cameroon NR NR/ (34%) No Steroids + DEC 3 weeks/NR
25, 1999 F, 25 Traveler USA USA/Gabon NR NR/ (44%) Calabar swellings;
three nodules (ﬁnger,
arm, breast); nodule
biopsy positive for
Loa loa
DEC 6 courses; mebendazole 7 doses;
suramin; albendazole 3 weeks/
recurrence at 19 months
26, 2002 M, 38 Immigrant Ghana Belgium/Nigeria (1985) and Ivory
Coast (1986)
Yes/15.2 mff/ml NR/no No Surgical extraction; DEC 2 weeks/NR
27, 2002 M, 30 Immigrant Cameroon Germany, 5 years/Cameroon NR NR/ (7.8%) No DEC 3 weeks/NR
28, 2002 M, 28 Immigrant Cameroon Germany, 5 weeks/Cameroon NR NR/NR No Surgical extraction/NR
29, 2004 F, 35 Expatriate Germany Germany/Central Africa 6 month
stay 5 years before
No NR/ (25%) Calabar swellings Surgical extraction; DEC 3 weeks +
mebendazole/NR
30, 2005 M, 43 Immigrant Nigeria USA 9 years/Nigeria No NR/No No Surgical extraction/lost to follow-up
31, 2005 F, 34 Immigrant Cameroon Switzerland 2 years/Cameroon Yes/418 mff/ml NR/ (19.6%) Calabar swellings Albendazole 2 weeks; steroids +
DEC 3 weeks/NR
31, 2005 F, 17 Immigrant Cameroon Switzerland 12 years/Cameroon No NR/NR Calabar swellings Surgical extraction/NR
31, 2005 F, 31 Traveler Switzerland Switzerland/Cameroon 8 years before No NR/yes No Albendazole 3 weeks; steroids +
DEC 4 weeks/NR
31, 2005 F, 45 Immigrant Cameroon Switzerland/Cameroon NR NR/yes No Albendazole 2 weeks; steroids +
DEC 4 weeks/NR
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Table 1 (Continued )
Reference,
year of
publication
Sex, age
(years)
Status Country of
origin
Country of residency/travel Microﬁlaremia/
concentration
WBC/eosinophils,109/l
(% eosinophils)
Other manifestations Treatment/follow-up
32, 2006 M, 23 Immigrant Africaa Germany 5 years/Africa No NR/NR Calabar swellings Surgical extraction, DEC 3 weeks/NR
33, 2006 F, 8 Immigrant Equatorial
Guinea
Spain, 6 years/travel to Equatorial
Guinea 2 years before
No NR/0.700 Calabar swellings;
urticaria
DEC 3 weeks/NR
34, 2006 M, 34 Traveler UK UK/Cameroon 12 years before Yes/2000 mff/ml NR/1.520 No Surgical extraction; albendazole
3 weeks/NR
35, 2006 F, 20 Immigrant Cameroon Switzerland/Cameroon (last visit
5 years earlier)
Yes/820 mff/ml NR/ (18.5%) Hepatitis following
ivermectin treatment
Albendazole 3 weeks; ivermectin
single dose; DEC 4 weeks/NR
36, 2007 M, 24 Immigrant Cameroon Spain, 6 years/visiting country of
origin once a year
NR NR/NR No Surgical extraction/NR
37, 2007 M, 27 Immigrant Democratic
Republic of
Congo
Spain for 8 months/
Democratic
Republic of Congo
Yes/NR 4.1/0.287 (7%) No Surgical extraction; albendazole
3 weeks/NR
38, 2008 F, 29 Expatriate Mauritius Korea, 5 years/Cameroon
(from 1996
to 2000)
Yes/NR NR/ (37%) Calabar swellings Surgical extraction; ivermectin
single dose/lost to follow-up
39, 2008 M, 42 Immigrant Nigeria Australia 2 years/Nigeria Yes/NR NR/1.180 No Surgical extraction; albendazole
3 weeks/NR
40, 2008 M, 30 Immigrant Cameroon USA 2 years/Cameroon Yes/4910
mff/ml
6.4/0.512 (8%) No Apheresis + steroids + DEC 3 weeks/NR
41, 2008 M, 29 Immigrant Gabon USA/Gabon No 4.3/0.391 (9.1%) No Surgical extraction/NR
42, 2009 F, 38 Expatriate Norway Norway/Congo 2 years No NR/NR Subcutaneous
worm migration
Surgical extraction; DEC/NR
43, 2010 F, 33 Traveler Switzerland
(Italy)
Switzerland/Angola 7 years
before
No NR/ (8%) No Surgical extraction/NR
44, 2010 M, 25 Traveler USA USA/Equatorial Guinea
2 years before
(12 days)
No NR/yes Calabar swellings DEC/6 months asymptomatic
45,c 2010 F, 21 Traveler UK UK/Nigeria 6 years before Yes/125 mff/5ml NR/yes Calabar swellings Surgical extraction; steroids + DEC/NR
46, 2011 M, 35 Immigrant Ghana UK/Ghana 8 years before NR NR/NR No Surgical extraction/NR
46, 2011 F, 20 Immigrant Cameroon UK/Cameroon 6 years before NR NR/NR No Surgical extraction/NR
47, 2011 F, 37 Immigrant France UK/Congo Yes/55 mff/20ml NR/NR No Surgical extraction; ivermectin single
dose; steroids + DEC 3 weeks/12 months
asymptomatic
PR, 2011 F, 27 Immigrant Cameroon Italy/Cameroon 7 years before Yes/400 mff/ml 6.9/0.897 (13%) Calabar swellings Ivermectin + steroids; albendazole 2
weeks; steroids + DEC 3 weeks/17
months asymptomatic
PR, 2011 F, 25 Immigrant Cameroon Italy/Cameroon 1 year before No 5.31/0.080 (1.5%) No Ivermectin; DEC + steroids 3 weeks/6
months asymptomatic
CSF, cerebrospinal ﬂuid; DEC, diethylcarbamazine; F, female; M, male; mff, microﬁlariae; NR, not reported; PR, present report; ST, standard treatment (drug not speciﬁed); WBC, white blood cells.
a Country not reported.
b Case reported twice (Campo S, Carta S, Gasparri V, Nowakowski M. Peripheral eosinophilia due to ‘‘Loa loa’’ infection. Eur J Intern Med 1995;6:127–8).
c This case was also reported in reference 46.
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Table 2
Fifty-three cases of imported loiasis presenting with manifestations other than ocular, published between January 1986 and December 2011
Reference,
year of
publication
Sex, age
(years)
Status Country of
origin
Country of residency/travel Microﬁlaremia/
concentration
WBC/eosinophils,
109/l (%
eosinophils)
Clinical manifestations Radiographic ﬁndings Treatment/follow-up
48, 1986 M, 28 Immigrant Cameroon France/Cameroon Yes/35000 mff/ml NR/1.600 Itching, proteinuria, hematuria;
kidney biopsy: evidence of
Loa loa microﬁlariae in
glomeruli and vessels
ND Apheresis + steroids +
DEC 3 weeks/9 months
asymptomatic
49, 1986 F, 4 Expatriate USA USA/Central African
Republic 1 year
No 25.3/15.433 (61%) Recurrent Calabar swellings ND DEC 2 cycles of 2 weeks
/36 months
asymptomatic
50, 1987 F, 5 Expatriate USA USA/Cameroon No NR/ (30%) Recurrent Calabar swellings ND DEC 3 weeks/NR
8, 1988 M, 32 Expatriate Germany Germany/Nigeria Yes/4340 mff/ml 13.4/7.900 (59%) Routine check-up: eosinophilia ND Apheresis (4 cycles)
+ ST
51, 1989 F, 37 Expatriate France France/Gabon 4 years Yes/ND 7.6/2.736 (36%) Ascites due to liver cirrhosis;
Loa loa identiﬁed in ascitic ﬂuid
ND DEC 4 weeks/NR
52, 1989 M, 27 Immigrant Cameroon France 4 years/Cameroon
every year
Yes/NR 5.4/0.324 (6%) Mild fever (37.5 8C) and acute
knee arthritis; Loa loa
microﬁlariae identiﬁed in
knee effusion
ND Steroids + DEC 3
weeks/NR
53, 1989 F, 40 Expatriate Sweden Sweden/Congo No NR/NR Breast lesion; history 13 years
before of Calabar swellings
and eye worm migration
Mammography: multiple
spiral- and rod-shaped
calciﬁcations
NR
54, 1990 M, NR Immigrant Cameroon Switzerland/Cameroon NR 8.9/0.890 (10%) Calabar swellings; acute arthritis Knee radiograph: negative DEC 3 weeks/NR
55, 1990 F, 56 Immigrant Cameroon USA/Cameroon No 4.5/0.130 (3%) Routine check-up;
breast biopsy: calciﬁed dead worm
Mammography: linear and
rounded calciﬁcations
NR/NR
56, 1991 M, 32 Expatriate New Zealand UK/Gabon, Nigeria No NR/3.500 Recurrent Calabar swellings; carpal
tunnel syndrome; lymphadenopathy
and splenomegalya
ND DEC 3 weeks/NR
57, 1992 F, 29 Expatriate USA USA/Gabon NR NR/NR Recurrent Calabar swellings; breast
biopsy: positive for Loa loa
Mammography: serpiginous
calciﬁcation within a lesion
NR/NR
58, 1992 M, 40 Immigrant Ghana USA 6 months/Ghana Yes/590 mff/ml 18.4/0.184 (1%) Chest pain, productive cough,
dyspnea, intermittent fever;
thoracentesis: Loa loa in pleural ﬂuid
Chest X-ray: pleural effusion Apheresis + steroids
+ DEC 3 weeks/4
months asymptomatic
59, 1992 M, 46 Traveler France France/Cameroon, Congo
4 months earlier
No NR/4.000 Acute arthritis (positive
serology for Loa loa)
ND Steroids + DEC 2
cycles of 3 weeks/NR
60, 1993 M, 38 Expatriate USA USA/Gabon No 8.6/1.720 (20%) Recurrent Calabar swellings Arm X-ray: subcutaneous
edema
DEC 3 weeks/3
months
asymptomatic
60, 1993 F, 39 Expatriate USA USA/Nigeria No 7.5/0.375 (5%) Recurrent Calabar swellings ND DEC 3 weeks/NR
60, 1993 F, 53 Traveler USA USA/Nigeria No 4.9 (normal) Recurrent Calabar swellings ND DEC 3 weeks/NR
61, 1993 F, 35 Immigrant Africab Belgium/Africa Yes/>1000 mff/ml NR/0.390 Infertility; Loa loa from oocyte
retrievalc
ND NR/NR
62, 1993 M, 23 Expatriate USA USA/Democratic Republic
of Congo
No 13.1/3.013 (26%) Recurrent Calabar swellings ND DEC 3 weeks/NR
63, 1994 M, 52 Immigrant Cameroon France/Cameroon Yes/150 mff/ml 16.2/4.860 (30%) Calabar swellings; weight loss,
arthro-myalgias, dry cough
Chest X-ray and CT scan:
apical lobe inﬁltrate
Steroids;
ivermectin single dose +
DEC 3 weeks/4 months
asymptomatic
64, 1994 F, 26 Expatriate Spain Spain/Equatorial Guinea
for 2 years
Yes/NR NR/3.720 Calabar swellings ND DEC 3 weeks/NR
65, 1995 F, 13 Expatriate USA USA/Cameroon 7 years
earlier (for 18 months)
No 19.9/3.675 (29%) Recurrent Calabar swellings;
eye worm migration
Plain X-ray foot and ankle:
no bony abnormalities or
evidence of effusion
Surgical extraction; DEC
3 weeks/3 months
asymptomatic
66, 1996 M, 24 Traveler USA USA/Cameroon, Niger,
Nigeria 3 years earlier
ND NR/NR None reported (examination
for a trauma)
US abdomen: multiple
hypodense lesions in the
spleen
Splenectomy;d DEC/12
months asymptomatic
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Table 2 (Continued )
Reference,
year of
publication
Sex, age
(years)
Status Country of
origin
Country of residency/travel Microﬁlaremia/
concentration
WBC/eosinophils,
109/l (%
eosinophils)
Clinical manifestations Radiographic ﬁndings Treatment/follow-up
66, 1996 F, 27 Traveler USA USA/Nigeria 5 years earlier No NR/3.500 None reported (employment
examination); 2 months after
splenectomy, eye worm
migration and Calabar swellings
US and CT abdomen:
multiple hypoechoic
lesions in the spleen
Splenectomy;d DEC/24
months asymptomatic
67, 1997 M, 27 Immigrant Cameroon France/Cameroon Yes/400 mff/ml NR/1.060 Chronic proteinuria, microscopic
hematuria;e kidney biopsy:
evidence of Loa loa microﬁlariae
within glomeruli
ND Ivermectin 2 doses/NR
68, 1997 M, 43 Expatriate USA USA/Gabon 6 years earlier Yes/NR NR/ (18%) Exertional dyspnea with restrictive
pattern on pulmonary function tests;
Loa loa microﬁlariae identiﬁed in BAL;
Calabar swellings and one episode of
eye worm migration
Chest X-ray: bilateral
interstitial inﬁltrates
Apheresis; DEC 3 weeks;
8 weeks asymptomatic
69, 1998 M, 49 Expatriate Denmark Denmark/Cameroon ND NR/3.370 Pain and swelling forearm
(thrombosis ulnar veins)
US: normal venous ﬂow
from the cubital vein;
contrast venography:
occlusion of the ulnar
veins
DEC 3 weeks/6
months asymptomatic
70, 1998 F, 17 Immigrant Cameroon Switzerland 2 years/
Cameroon
Yes/NR NR/No Recurrent subcutaneous worm migration ND Surgical extraction + DEC
4 weeks/NR
71, 1998 M, 38 Immigrant Philippines USA/Democratic Republic
of Congo 3 years
NR NR/ (47%) Calabar swellings, pruritus NR NR/NR
72, 1998 F, 71 Immigrant Cameroon France/Cameroon
10 years earlier
NR NR/NR Routine check-up; Mammography: linear
calciﬁcations
NR/NR
72, 1998 F, 36 Immigrant Cameroon France/Cameroon
18 years earlier
NR NR/NR Mastodynia Mammography: linear
calciﬁcations
NR/NR
25, 1999 F, 27 Expatriate USA USA/Gabon 3 years NR NR/1.869 Recurrent Calabar swellings ND DEC 4 courses of 3 weeks;
albendazole 3 weeks/84
months asymptomatic
25, 1999 M, 29 Expatriate USA USA/Gabon No NR/1.160 Recurrent Calabar swellings ND DEC 3 courses of
3 weeks; albendazole 3
weeks/84 months
asymptomatic
73, 2001 M, 21 Traveler UK UK/West-Central Africa Yes/NR 22.1/14.900 (67%) Calabar swellings; proteinuria,
microhematuria, leg edema
(nephrotic syndrome); kidney
biopsy: MCGN
ND DEC 2 courses of 3 weeks/
22 months, 1 relapse
74, 2001 F, 55 Immigrant Cameroon Switzerland/Cameroon Yes/152 mff/ml 6.51/0.846 (13%) Unspeciﬁed; delirium following
3 days of albendazole
MRI: focal lesions in the
white matter compatible
with small infarcts
Albendazole 3 days/1
month asymptomatic
75, 2002 F, 33 Immigrant Nigeria USA/Nigeria 3 years before Yes/3800 mff/ml NR/2.600 (32%) Recurrent Calabar swellings ND Apheresis + steroids;
DEC 3 weeks/3 months
asymptomatic
(negative blood ﬁlm
and PCR)
76, 2002 F, 24 Expatriate USA USA/Gabon 31 months earlier No 15.6/4.992 (32%) Recurrent Calabar swellings;
muscle cramps; hepatomegaly
ND DEC 3 weeks/NR
77, 2002 M, NR Immigrant Cameroon Italy/Cameroon Yes/NR NR/ (15%) Itching, paresthesia, headache,
arthralgias
ND Albendazole 3 weeks/NR
78, 2003 F/19 Immigrant Cameroon USA 4 years/Cameroon NR NR Routine gynecological examination;
Loa loa identiﬁed in Pap test
ND NR/NR
79, 2004 F, 73 Traveler Switzerland Switzerland/Cameroon Yes/2500 mff/ml NR/0.910 (13%) Calabar swellings; dyspnea, weight
loss; thoracentesis: Loa loa
identiﬁed in pleural ﬂuid
Chest X-ray and CT:
pleural effusion and
mediastinal massf
Steroids; DEC 3
weeks; albendazole
3 weeks/14 months
asymptomatic
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Table 2 (Continued )
Reference,
year of
publication
Sex, age
(years)
Status Country of
origin
Country of residency/travel Microﬁlaremia/
concentration
WBC/eosinophils,
109/l (%
eosinophils)
Clinical manifestations Radiographic ﬁndings Treatment/follow-up
80, 2004 F, 28 Immigrant Nigeria Spain/Nigeria Yes/1000 mff/ml 7.5/1.500 (20%) Recurrent Calabar swellings ND DEC 3 weeks/NR
81, 2005 F, 39 Traveler Spain Spain/Cameroon No NR/ (40%) Recurrent Calabar swellings ND Albendazole 4
weeks/9 months
asymptomatic
82, 2005 M, 44 Immigrant Equatorial
Guinea
Spain/Equatorial Guinea
1 year earlier
Yes/300 mff/ml 6.38/0.976 (15.3%) Recurrent Calabar swellings ND DEC 3 weeks/3 months
asymptomatic
83, 2006 F, 14 Expatriate Germany Germany/Cameroon Yes/5000 mff/ml NR/1.200 (17%) None reported (routine blood
examination)
ND Albendazole 3 weeks;
DEC 3 weeks/NR
84, 2008 F, 21 Traveler Japan Japan/Cameroon No 7.3/2.190 (30%) Recurrent Calabar swellings; eye
worm migration
ND Ivermectin 2 courses
of 1 day/7 months
asymptomatic
85, 2008 F, 41 Immigrant Cameroon USA/Cameroon Yes/3270 mff/ml NR/0.350 (5%) None reported; examination for
infertility with Loa loa isolated
from ovarian follicular ﬂuid
ND Apheresis; single dose
ivermectin; DEC
3 weeks/NR
86, 2009 M, 36 Immigrant Senegal France/Gabon Yes/8000 mff/ml NR/0.810 Intermittent gross hematuria;
kidney biopsy showed intralumen
Loa loa microﬁlariae
ND Steroids + ivermectin
1 dose + DECg/NR
87, 2010 M, 69 Immigrant Equatorial
Guinea
Spain/Equatorial Guinea Yes/NRh NR/2.600 Itching, myalgias, productive cough ND DEC + mebendazole
4 weeks/NR
88, 2010 M/42 Immigrant Equatorial
Guinea
Spain/Equatorial Guinea Yes/220 mff/mlh NR/1.700 Proteinuria, hypertension, anasarca
(nephrotic syndrome); kidney biopsy:
collapsing glomerulopathy
ND DEC 3 weeks/24
months asymptomatic
89, 2010 M, 26 Immigrant USA USA/West-Central Africa Yes/>3000 mff/ml NR/2.800 (18%) Blood eosinophilia (2 years) ND Apheresis + steroids;
DEC/NR
90, 2011 F, 28 Expatriate Italy Italy/Gabon 3 years earlier Yes/172 mmf/13 ml NR/3.300 Recurrent Calabar swellings;
peripheral neuropathy
US abdomen: multiple
hypoechoic lesions in
the spleen
Steroids; ivermectin
single dose + albendazole
4 weeks/12 months
asymptomatic
91, 2011 M, 28 Immigrant Nigeria Italy/Nigeria 6 months
earlier
Yes/7000 mff/ml 5.44/2.284 (42%) Blood eosinophilia Chest X-ray: negative;
US abdomen: negative
Steroids; ivermectin
2 doses + albendazole
3 weeks/2 months
persistence of microﬁlariae
92, 2011 F, 17 Immigrant Equatorial
Guinea
Spain/Equatorial Guinea
3 months earlier
Yes/NR NR Check for anemia during pregnancy ND Mebendazole/1 month
after meningoencephalitis
PR, 2011 M/58 Expatriate France France/Gabon 8 years
before
Yes/20–30 mff/ml 6.5/1.040 (16%) Calabar swellings, pruritus; eye and
subcutaneous worm migration
ND DEC 2 weeks; doxycycline
3 courses of 6 weeks;
ivermectin single dose/
relapse before ivermectin
administration;
asymptomatic at 60
months
BAL, bronchoalveolar lavage; CT, computed tomography; DEC, diethylcarbamazine; M, male; F, female; MCGN, type 1 mesangiocapillary glomerulonephritis; mff, microﬁlariae; MRI, magnetic resonance imaging; ND, not
determined; NR, not reported; ST, standard treatment (drug not speciﬁed); US, ultrasound; WBC, white blood cells.
a A diagnosis of Trypanosoma brucei gambiense was established and treated with suramin.
b Country not reported.
c According to the authors, microﬁlariae probably originated from inadvertent puncture of small vessels on the ovarian surface.
d Both patients underwent splenectomy for a suspected lymphoma with subsequent diagnosis of loiasis.
e Discovered during hospitalization for malaria.
f Thymoma diagnosis after excision.
g The patient developed encephalopathy and worsening proteinuria after DEC administration; microﬁlariae were recovered from cerebrospinal ﬂuid and urine.
h Double infection with Loa loa and Mansonella perstans.
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Table 3
Clinical and laboratory ﬁndings among immigrants in comparison with travelers/expatriates in the present series and in two other published series
Present series p-Value Churchill et al.95 p-Value Klion et al.96 p-Value
Expatriates/travelers Immigrants Expatriates Immigrants Non-endemic Endemic
Number of patients 47 54 - 49 51 - 42 51 -
Sex (M/F) 16/31 33/21 p = 0.01 28/21 19/32 p = 0.07 24/18 51/0 NR
Age (median, range), years 30 (4–73) 30 (8–71) p = 0.9 33.4 (13–67) 25.6 (8–40) p = 0.0001 26 (6–49) 37 (19–55) p = 0.2
Interval of time from
ﬁrst/last potential
exposure and
diagnosis (range)
108 (2–576)
weeksa
200 (2–864)
weeks
p = 0.2 15 (5–156)
monthsb
276 (18–468)
months
p < 0.0001 24 (6–48)
months
252 (12–600)
months
NR
Microﬁlaremia 19/42 (45.2%) 32/41 (78%) p = 0.1 14 (29%) 38 (75%) p < 0.0001 4 (9.5%) 46 (90.2%) p < 0.001
Geometric mean + SD 2913 + 3421
(n = 8)
3449 + 7242
(n = 23)
p = 0.98 35 (n = 6) 1024 (n = 19) p = 0.012
Eosinophilia 41/43 (95.3%) 28/41 (68.3%) p = 0.3 45/48 (94%) 33/49 (67%) p = 0.0025 42 (100%) 27 (52.9%) p < 0.001
Geometric mean 4042 + 3971
(n = 26)
1251 + 1199
(n = 29)
p < 0.0001 3382 747 p < 0.0001 3026 370 p < 0.001
Eye worm migration 25/47 (53.2%) 29/54 (53.7%) p = 0.88 8 (16%)c 23 (45%) p = 0.0038 4 (10%) 8 (16%) p = 0.6
2 (4%)d 9 (18%) p = 0.07
Calabar swelling 30/46 (65.2%) 12/54 (22.2%) p = 0.01 40 (82%)c 18 (35%) p < 0.0001 40 (95%) 8 (16%) p < 0.001
24 (49%)d 10 (20%) p = 0.0039
Other manifestations 17/47 (36.2%) 20/54 (37%) p = 0.89 2 (4%) 5 (10%) NS 12 (28.6%) 11 (21.6%) NS
F, female; M, male; NR, not reported; NS, not signiﬁcant; SD, standard deviation.
a Median time since last exposure.
b Median time since ﬁrst exposure.
c History.
d Actual ﬁnding.
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was not speciﬁed in nine cases;8,11,14,16,29,49,61,73,89 75% of
the infestations were acquired in the countries of Cameroon (38/
92, 41.3%), Nigeria (19/92, 20.7%), and Gabon (12/92, 13.0%)6–
8,10,12,13,15,17–20,23–28,30,31,34–36,38,40,41,45,46,48,50–52,54,55,57,59,60,63,65,
67–70, 72,74–81,83–86,90,91 (including PR cases). For three patients, more
than one country had been visited (Gabon and Nigeria,56 Cameroon
and Congo,59 and Cameroon, Nigeria, and Niger66). Microﬁlaremia
was more common in immigrants (78.0%)7,13,21–
23,26,31,35,37,39,40,47,48,52,58,61,63,67,70,74,75,80,82,85–88,91,92 (including PR
cases) than in expatriates and travelers (Table 3). In contrast,
peripheral blood eosinophilia (95.3%)8–12,14,16,18–20,25,29,31,34,38,43–
45,49–51,56,59,60,62,64–66,68,69,73,76,79–81,83,84,90 (and PR) and Calabar
swellings (65.2%) 10,18,20,25,29,38,44,45,49,50,53,56,57,60,62,64,65,68,73,76,79,
81,84,90 (and PR) were more often observed in expatriates/travelers
than in immigrants. Ocular eye worm migration was observed to the
same extent in immigrants (53.7%)6,7,13,15,17,21–24,26–28,30–33,35–37,39–
41,46,47 (and PR) and in expatriates/travelers (53.2%)8–12,16,18–
20,29,38,42,45,53,65,66,68,84 (and PR).
Four patients also experienced subcutaneous worm migra-
tion7,42,70 (and PR). Other unusual manifestations included
pulmonary involvement,58,63,68,79 acute arthritis,52,54,59 carpal
tunnel syndrome,56 calciﬁed breast nodules containing the
nematode,25,53,55,57,72 skin nodules,25 splenic lesions,66,90 vein
thrombosis,69 nephrotic syndrome,48,67,73,86,88 infertility,61,85 and
peripheral neuropathy.90 Apart from detection in peripheral blood,
microﬁlariae were detected in ascitic ﬂuid,51 pleural effusion,58,79
and bronchoalveolar lavage,68 ovarian follicular ﬂuid, oocytes, and
cervicovaginal cytology specimens,61,78,85 breast and kidney
biopsies,48,55,57,67,86 knee effusion,52 cerebrospinal ﬂuid and
urine,86 and from spleen tissue after splenectomy.66
Of those patients presenting with ocular loiasis, 21 were treated
with medical therapy (15 with DEC, two with DEC plus
mebendazole, two with albendazole, one with ivermectin, and
one with ivermectin plus DEC) associated with surgical extraction
of the adult worm from the eye.6,7,9,10,12–14,16,17,19,21,26,29,32,34,37–
39,42,45,47 Nine patients underwent surgical extraction on-
ly.15,28,30,31,36,41,43,46 Eighteen patients were treated with different
schemes of therapy: sequential administration of albendazole andDEC,31 DEC alone,23,40,44 ivermectin followed or preceded by
albendazole and DEC35 (and PR), and multiple courses of DEC
followed by mebendazole and albendazole.25 Patients presenting
with clinical manifestations different from eye worm migration
(Table 2) were treated with DEC in 24 cases,48–52,54,56,58–
60,62,64,65,68–70,73,75,76,80,82,88,89 and by splenectomy done for
suspected splenic lymphoma followed by DEC in two patients.66
Ivermectin was employed alone in two patients,67,84 and followed
by DEC or albendazole in ﬁve patients.63,85,86,90,91 Two patients
treated with multiple unsuccessful courses of DEC were subse-
quently treated with albendazole,25 whereas another two patients
were treated with albendazole plus DEC.79,83 Albendazole alone
was employed in two patients.77,81 Finally, in another four cases
the drug used was not speciﬁed.8,53,55 Overall, 11 subjects
underwent apheresis to reduce the high microﬁlarial
loads,8,13,23,40,48,58,68,80,85,89 and 26 patients received corticosteroid
therapy prior to antiﬁlarial drug treatment in order to avoid high
antigen release12,13,18,19,22–24,31,40,47,48,52,58,59,63,75,79,86,89–91 (and
PR).
An acute hepatitis35 and a nephropathy with proteinuria and
hematuria67were probably precipitated following ivermectin single
dose consumption. Two patients developed encephalitis following
DEC administration: a severe picture (with a Glasgow coma scale
score of 9) together with worsening proteinuria in one case86 and
with lethargy and frontal release signs in the other patient.22 The
latter patient also had microﬁlariae disclosed in the cerebrospinal
ﬂuid. Both recovered uneventfully after stopping DEC and subse-
quently resumed the drug without further problems. Moreover, one
case of encephalopathy with delirium and a case of meningoen-
cephalitis were described following treatment with albendazole and
mebendazole.74,92
A follow-up period was reported for only 35 (34.7%) patients
overall (including our three patients) for a length of time ranging
from 1 to 84 months (median 10.5 months)7,12,14,16,17,23,25,44,47–
49,58,63,65,66,68,69,73–75,79,81,82,84,88,90,91 (and PR). With the exception
of four patients, one of whom had a relapse of microﬁlaremia
3 months after the end of treatment,16 one with persistence of
microﬁlaremia 2 months later,91 and two patients with the
recurrence of symptoms,25,73 the remaining 31 patients remained
S. Antinori et al. / International Journal of Infectious Diseases 16 (2012) e649–e662 e659asymptomatic during the follow-up.7,12,14,17,25,47–49,58,63,65,66,68,69,
73–75,79,81,82,84,88,90,91 (and PR).
5. Discussion
In this review we analyzed 101 cases of loiasis (including the
three reported here by us) observed outside endemic areas and
published in the literature in the last 25 years. Although possibly
biased by the fact that the analysis was based generally on single
case reports observed in different countries over a long period of
time, it allowed us to compare the clinical presentation among
different populations (i.e., expatriates/travelers versus immi-
grants) with a sample size of the same order as the two largest
studies previously published on this topic.95,96 Over 91% of all cases
were observed in Europe (60.4%)8,12,16,17,19–21,24,26–29,31–37,42,43,45–
48,51–54,56,59,61,63,64,67,69,70,72–74,77,79–83,86–88,90–92 (and PR) and
the USA (30.7%).6,13,15,22,23,25,30,40,44,49,50,55,57,58,60,62,65,66,68,71,75,76,
78,85,89
In our case series, the length of time from the last potential
exposure to the time of appearance of clinical symptoms was an
overall median of 120 weeks (range 2–864 weeks), with 108 weeks
for expatriates/travelers (range 2–576 weeks) and 200 weeks for
immigrants (2–864 weeks). In the retrospective study of Churchill
et al., the median time since ﬁrst exposure to appearance of
symptoms was 15 months (range 5–156 months) for expatriates
and 276 months (range 18–468 months) for immigrants.95
Although adopting the ﬁrst or last potential exposure to areas of
endemicity to measure the ‘clinical prepatency’ made a compari-
son of the results of the present study with those of Churchill et al.
unfeasible, and recognizing that both are imprecise and biased
variables, it is nevertheless evident that a difference exists in the
time of presentation, which is much longer for immigrants in
comparison with expatriates/travelers. This is conﬁrmed by recent
data from the GeoSentinel Network showing that the majority of
patients with Loa loa infection had traveled for between 1 and 6
months and that 77% of patients with loiasis (excluding visiting
friends and relatives and immigrants) presented within 1–6
months after their return.97 Although it is commonly believed that
prolonged exposure in an endemic area is necessary for the
acquisition of Loa loa infection, more recent data seem to suggest
that infection can also occur after short periods of exposure, such
as those commonly observed in travelers, and in this regard both
Moffet et al. and Landry et al. have reported the development of
loiasis after an exposure as short as 12 days.44,79 Thus, it is
important to consider this diagnosis not only in immigrant and
expatriates, but also in travelers who visit endemic areas for even
short periods of time.
Overall, eosinophilia was observed in 82.1% of patients and
microﬁlaremia was detected in 61.4% of all cases described here;
the possible absence of microﬁlariae in the peripheral blood of
people who have suffered from subconjunctival migration of at
least one adult worm is a well known phenomenon called occult
loiasis.98 A genetic predisposition has been implicated as a
mechanism responsible for the patient becoming microﬁlaremic
once infected by Loa loa.99 A more recent study conducted in
Cameroon showed that the acquisition of microﬁlaremia is gender-
dependent (males being more frequently affected than females)
and associated with a higher level of exposure to infective
larvae.100 Nevertheless, in agreement with the two previous
studies comparing the clinical presentation of loiasis among
visitors to endemic areas and natives of these areas who have
either migrated or not to non-endemic countries, our review of the
literature conﬁrms that peripheral blood eosinophilia and Calabar
swellings are observed much more frequently among expatriates
and travelers and conversely that the presence of blood micro-
ﬁlaremia is more common among immigrants.95,96 However, incontrast to the results reported in the study of Churchill et al.,95 we
were unable to demonstrate a much higher frequency of eye worm
migration among immigrants in comparison with expatriates/
travelers. Interestingly, Klion et al.,96 comparing unselected
patients from Benin with a selected group of expatriates referred
to their center, found a very low prevalence of eye worm migration
in both groups with no statistically signiﬁcant difference.
As well as the two characteristic and well known clinical
features that are commonly associated with Loa loa infestation, i.e.,
Calabar swellings and subconjunctival migration of the adult
parasites, in the present review we noted other manifestations that
are quite unusual, some which are not mentioned in tropical
medicine textbooks. These include ﬁve patients with a nephropa-
thy characterized by a nephrotic syndrome in four
cases,48,67,73,86,88 splenic lesions in three patients, two of whom
underwent splenectomy for a suspected lymphoma,66,90 and four
patients with pulmonary involvement58,63,68,79 presenting with
pleural effusion in two cases58,68 and lobar or interstitial inﬁltrates
in the other two cases.63,79 Also ﬁve women had breast nodules
(containing Loa loa in three cases), which were disclosed either on
routine check-up mammography or during the work-up investi-
gation of a palpable breast lesion.53,55,57,72 Five cases of calciﬁca-
tion of the breast attributed to Loa loa have previously been
reported in Congolese women, but have also been observed in
association with Wuchereria bancrofti.101,102 Finally, three patients
with acute arthritis,52,54,59 one patient with leukocytoclastic
vasculitis,60 and two patients with infertility in whom Loa loa
were identiﬁed in follicular liquid and oocytes were described.61,85
Among the above cited unusual features, renal involvement
characterized by proteinuria and hematuria is probably the most
frequent, being observed by Klion et al. in a similar percentage of
patients from endemic and non-endemic areas (22% and 21%,
respectively).95 Although the mechanism responsible for renal
involvement is unknown, immune complexes67,73,86,88 were
observed in four patients and microﬁlariae67,86 in two. However,
the four patients with a nephrotic syndrome had complete
remission after treatment with DEC or ivermectin.48,67,73,88 It is
worth noting that a nephrotic syndrome with focal segmental
glomerulosclerosis and microﬁlariae within afferent glomerular
arterioles has been described in a Congolese woman who died of
renal failure, and another unproven case of glomerulopathy has
been reported in another Congolese man also presenting with
encephalopathy despite antiﬁlarial treatment.103,104
Pulmonary involvement was described in the study of Klion
et al. in only two expatriates (5%), one with pleural effusion and the
other with a pulmonary inﬁltrate.95 Interestingly two of the four
patients with pulmonary involvement reviewed here had pleural
effusion and in both cases microﬁlariae were identiﬁed in the
pleural ﬂuid.58,79 We are aware of another case of pleural effusion
with microﬁlariae of Loa loa identiﬁed in the pleural ﬂuid in a
Cameroonian HIV-positive patient who was successfully treated
with ivermectin.105
Regarding our case series, both women originating from
Cameroon had been living in Italy for 7 years when they presented
with ocular loiasis. However, the second patient had visited her
country of origin 1 year before. Interestingly, the ﬁrst woman
recalled a previous episode of eye worm at the age of 17 years
when she was living in Cameroon. Therefore, we can assume that
the infestation in the latter case dates back at least 10 years; it has
been shown that microﬁlariae usually mature into adult worms in
approximately 1 year, but this process can take up to 4 years and
the adult worms can live for up to 17 years in the human host.1
The second point of interest with regard to the ﬁrst case
presented here is the diagnosis of ocular ﬁlariasis during
pregnancy, which gives rise to two major questions: the ﬁrst
about drug management of this condition during pregnancy and
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issue that remains controversial. An old report of two cases of
asymptomatic loiasis discovered during pregnancy indicated that
treatment with DEC was employed after delivery and that there
was no evidence of microﬁlariae crossing the placenta.106 In
contrast, two case reports from Nigeria suggested transplacental
transmission of microﬁlariae of Onchocerca volvulus, the agent of
onchocerciasis.107,108 Moreover, transplacental migration and
transmission of the nematode W. bancrofti was demonstrated to
have occurred in a single case report from the USA involving a
Dominican woman109 and in at least 10% of microﬁlaremic women
from Haiti.110 In our case, despite the fact that microﬁlariae were
readily detected by microscopy in the placenta, the analysis of cord
and peripheral blood of the newborn were negative by both
microscopy and nested PCR. Moreover, when retested with both
methods at the age of 9 months, the patient’s daughter remained
negative, thus conﬁrming the absence of transplacental transmis-
sion of Loa loa. Finally, as far as treatment of a pregnant woman is
concerned, in accordance with the manufacturer’s indications we
ﬁrst attempted the treatment of our patient with ivermectin only
after delivery; she was then further treated with albendazole when
lactation had ended (i.e., when the baby was 4 months old).
However, as shown in Figure 2, we were only able to clear the
microﬁlariae from the peripheral blood of the mother by treatment
with DEC.
Our second case was remarkable for the fact that despite the
evident ocular passage of the adult worm, we were repeatedly
unable to demonstrate the presence of microﬁlaremia, not only by
microscopy but also using a nested PCR of peripheral blood drawn
at the same time. Previously, using the same protocol employed by
us, Toure´ et al. were able to demonstrate that this PCR assay is 100%
speciﬁc and 95% sensitive in detecting occult infection (i.e., patient
with adult worm passage but without demonstrable circulating
microﬁlariae).93
The utility of PCR in the diagnosis and management of loiasis is
actually unclear; its use in the ﬁeld has been suggested, with the
aim of identifying occult cases by screening large human
populations. Treatment of such properly identiﬁed cases will
result in a signiﬁcant reduction in the ‘community ﬁlarial load’.
Very recently researchers from Cameroon and the USA developed a
real-time quantitative PCR that is able to detect a single
microﬁlaria in a 20 ml dried blood spot (equivalent to a burden
of 50 microﬁlariae (mff)/ml).111 Although the authors acknowl-
edged that this method should be used in clinical laboratories
where real-time PCR equipment is available, they nevertheless
suggested the possibility of incorporating the target into loop-
mediated isothermal ampliﬁcation (LAMP), ultimately making its
use feasible at the point-of-care in endemic areas. However, in a
study conducted among returned expatriates, travelers, and
immigrants, the same authors showed that a real-time PCR
directed against Loa loa and W. bancrofti was equally sensitive
compared to blood ﬁltration for detecting microﬁlaremia of both
worms.112 Researchers from Spain used a nested PCR for Loa loa on
more than 500 blood samples and demonstrated a higher
sensitivity of molecular diagnosis in comparison with Knott’s
concentration technique.113
The third patient, a French man who had worked in Gabon for
several months, developed ocular loiasis 8 years after his stay in
Africa. Interestingly, clinical manifestations coincided with surgery
due to an aortic aneurysm. After an initial treatment with DEC he
underwent treatment with doxycycline, which failed to control
relapses of the disease. Doxycycline is generally used to eliminate
Wolbachia endobacteria that are harbored by many ﬁlarial
nematodes.94 However, by using electron microscopy, histology,
immunohistology, and PCR it has been shown that Loa loa ﬁlariae
do not harbor Wolbachia endobacteria in the numbers requiredeither for vertical transmission of the bacteria or for embryogene-
sis of the ﬁlariae.114 Thus, these results are against the use of
tetracycline for patients with microﬁlaremia due to Loa loa.
DEC, ivermectin, and albendazole are the drugs currently
employed for the treatment of loiasis, but each of them is
characterized by several limitations.1 DEC has long been the drug
of choice for the treatment of loiasis since it displays both micro-
and macro-ﬁlaricidal activity on the parasite. However, patients
with a high initial microﬁlarial load (>8000 mff/ml) are at risk of
developing serious reactions – ones that may be lethal – such as
encephalopathy.115 Another limitation of treatment with DEC is
the requirement of multiple courses of therapy in order to achieve
clinical and parasitological cure, as demonstrated by a study
conducted on expatriates who were followed-up for long periods
of time.116 A third possible limitation in the use of DEC, as
highlighted by the two cases observed in Italy, is the difﬁculty in
obtaining the drug; in fact DEC is no longer marketed in Europe and
is available in the USA only through the Centers for Disease Control
and Prevention (CDC).
Ivermectin has been claimed to have a marked microﬁlaricidal
effect against Loa loa lasting for at least 1 year after a single dose of
150/mg.117 However, it has no macroﬁlaricidal effect and a severe
encephalopathy has also been recognized following administration
of this drug in patients with a high microﬁlarial load.118 In the
present review a case of hepatitis and one of nephropathy were
registered after ivermectin treatment.35,67 The drug is generally
not recommended in pregnant and lactating women, but several
studies have suggested that the risk of congenital malformation or
abortion is not higher when the drug is inadvertently used in
pregnant women.119 Based on the fact that ivermectin levels in
human breast milk are low120 and on the recent recommendations
of the Mectizan Expert Committee, we used ivermectin (albeit
unsuccessfully) for the treatment of our ﬁrst patient when she was
lactating.121,122 Finally albendazole (at a dosage of 200 mg twice
daily for 3 weeks) has been shown to decrease microﬁlarial loads
progressively and slowly as a consequence of a primary
embryotoxic activity.123 In this regard it has been proposed that
albendazole be used in a sequential two-step treatment (before
DEC or ivermectin) for patients with a high level of microﬁlaremia
in order to avoid severe adverse effects.
The great heterogeneity of treatments registered among
patients reported in the present review is a matter of concern
and reﬂects problems with the availability of such drugs and the
absence of evidence-based guidelines. Moreover, only one patient
in three had a documented follow-up, showing a relapse in about
14% of cases, a ﬁgure that is similar to the experience reported by
Churchill et al. in London.95 However, it should be highlighted that
in the study by Klion et al.116 conducted on expatriates and
characterized by a stringent deﬁnition of successful treatment and
with a long follow-up, only 38% of patients were considered cured
after a single course of DEC.
Two more issues – apheresis to reduce high level microﬁlaremia
and eye surgery to remove the adult worm – are controversial and
deserve some comment.
In the mid-1980s, several case reports advocated the use of
apheresis to reduce microﬁlaremia before starting DEC thera-
py.8,48,124 However, in a recent review based on the guidelines of
the American Society for Apheresis, loiasis is not mentioned among
the infectious diseases that can be treated with this procedure.125
As far as the need to surgically extract the adult worm from the
eye during its ocular passage, it appears from our review that this
therapy is frequently employed (i.e., 31/52, 59.6%),6,7,9,10,12–
17,19,21,26,28–32,34,36–39,41–43,45–47,65 and in about 17% of cases this
was the only treatment performed in patients with the
disease.15,28,30,31,36,41,43,46 It might be anticipated that when
patients are ﬁrst seen by ophthalmologists this is the rule.
S. Antinori et al. / International Journal of Infectious Diseases 16 (2012) e649–e662 e661However, we believe that surgical extraction is generally
unnecessary (as seen in our patients), and as suggested more
authoritatively by the late Sir Patrick Manson a century ago
because: ‘‘it is safe to conclude that the particular loa that may
show itself about the eye or elsewhere is only one of many’’.126
Since we agree with this statement, whether or not the worm is
extracted it is essential to treat the patient with a systemically
active drug.
In conclusion, based on our experience together with the results
of the literature on imported loiasis, we expect that what we are
seeing in Europe and the USA might be the tip of the iceberg of a
neglected disease that could be emerging as the consequence of
increased travel and migration. Physicians should be aware of both
the typical manifestations and of possible unusual presentations:
in both cases the travel history is essential to guide the diagnosis in
the right direction.
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